Atomoxetine

Atomoxetine works differently from stimulant ADHD medications ^[1]. While stimulants primarily increase dopamine levels, atomoxetine selectively blocks the norepinephrine transporter (NET) in the brain, preventing norepinephrine from being reabsorbed back into nerve cells ^{[1, 2]}.

Norepinephrine is a key neurotransmitter involved in attention, impulse control, and executive function — the very skills that are impaired in ADHD ^[2]. By keeping more norepinephrine active in the prefrontal cortex (the brain region responsible for planning, focus, and self-regulation), atomoxetine helps improve attention, reduce hyperactivity, and control impulsive behavior ^{[1, 2]}.

Importantly, atomoxetine also indirectly increases dopamine in the prefrontal cortex (because NET also transports dopamine in this brain region), but it does not significantly affect dopamine in the nucleus accumbens — the brain's reward center ^[2]. This is why atomoxetine does not produce the euphoria or reinforcing effects associated with stimulants and has essentially no abuse potential.

Weeks 1-2: Unlike stimulants, atomoxetine does not work immediately ^[1]. During the first 1-2 weeks, you may notice some initial side effects (decreased appetite, stomach upset, mild headache) but limited ADHD improvement. This is normal — the medication needs time to build up in your system.

Weeks 3-4: Many patients begin noticing improvements in attention, focus, and impulse control around weeks 3-4 ^{[1, 2]}. Effects continue to build during this period.

Weeks 6-12: Full therapeutic benefit typically emerges over 6-12 weeks of consistent use ^[2]. Unlike stimulants, atomoxetine provides 24-hour coverage without the peaks and valleys in symptom control. Many patients appreciate the smooth, consistent effect and the lack of a 'crash' at the end of the day.

Sleep: Many patients find that atomoxetine actually improves sleep quality compared to stimulants, as it does not have the same activating effects late in the day ^[2].

Atomoxetine may be taken with or without food ^[1].

Food: Taking atomoxetine with food does not affect its overall absorption but may reduce the incidence of stomach upset and nausea, which are among the most common side effects ^[1]. Many clinicians recommend taking it with a meal, particularly when initiating therapy.

Alcohol: Alcohol should be avoided or used sparingly with atomoxetine. Both substances can impair judgment and cognitive function. Additionally, alcohol may worsen some side effects of atomoxetine such as dizziness and drowsiness.

Grapefruit: No significant interaction. Unlike many other medications metabolized by CYP enzymes, grapefruit does not meaningfully affect atomoxetine levels because it is primarily metabolized by CYP2D6 rather than CYP3A4.

Atomoxetine dosing is weight-based and individualized ^[1].

Children and adolescents (6-17 years, weighing up to 70 kg): - Starting dose: 0.5 mg/kg/day ^[1] - Target dose: Increase after a minimum of 3 days to approximately 1.2 mg/kg/day ^[1] - Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is less ^[1] - May be given as a single daily dose in the morning or split into two evenly divided doses (morning and late afternoon/early evening)

Adults and adolescents over 70 kg: - Starting dose: 40 mg/day ^[1] - Target dose: Increase after a minimum of 3 days to 80 mg/day ^[1] - Maximum dose: 100 mg/day ^[1] - May be taken once daily or divided into two doses

CYP2D6 poor metabolizers or use with strong CYP2D6 inhibitors: - Starting dose: 0.5 mg/kg/day (children) or 40 mg/day (adults) ^[1] - Increase only if well tolerated after 4 weeks to 1.2 mg/kg/day or 80 mg/day ^[1]

Hepatic impairment: Reduce dose to 50% (moderate) or 25% (severe) of normal dose ^[1].

Administration: Capsules should be swallowed whole — do not open, crush, or chew ^[1]. If a capsule is accidentally opened, wash any powder off skin or out of eyes immediately.

Atomoxetine is available as a generic medication, making it significantly more affordable than the original brand name Strattera ^{[1, 3]}.

Typical pricing (approximate 2025 prices): - Brand-name Strattera: $8-12 per capsule ($240-360/month) - Generic atomoxetine: $1-3 per capsule ($30-90/month)

Savings strategies: - Generic substitution: Generic atomoxetine has been available since 2017 and offers identical therapeutic effect at a fraction of the cost ^[3]. - Manufacturer coupons: Eli Lilly offered a savings card for Strattera, but with generic availability, most patients switch to generic. - Pharmacy discount programs: GoodRx and similar programs can reduce out-of-pocket costs for generic atomoxetine to as low as $25-40/month. - Insurance: Most insurance plans cover generic atomoxetine without prior authorization for ADHD diagnoses. Some plans may require a step-therapy protocol (trying a stimulant first).

Pregnancy: Atomoxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus ^[1]. Animal reproduction studies showed decreased fetal weight and skeletal variations in rabbits at doses that caused maternal toxicity. There are no adequate and well-controlled studies in pregnant women. Women should discuss the risks and benefits of continuing atomoxetine during pregnancy with their healthcare provider.

Breastfeeding: It is not known whether atomoxetine or its metabolites are excreted in human breast milk ^[1]. The drug and/or its metabolites were detected in rat milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, considering the importance of the drug to the mother.

Generic atomoxetine has been available in the United States since 2017, when Eli Lilly's patent exclusivity expired ^[3].

Brand name (Strattera): - Manufactured by Eli Lilly and Company - Available as 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg capsules - Significantly more expensive than generic

Generic atomoxetine: - Multiple manufacturers produce FDA-approved generic versions - Available in all the same strengths as brand-name Strattera - Rated therapeutically equivalent (AB-rated) by the FDA - The vast majority of prescriptions are now filled with generic

Note: Atomoxetine is the only FDA-approved non-stimulant in its specific pharmacological class (selective NRI) for ADHD. Other non-stimulant ADHD options include guanfacine ER (Intuniv) and clonidine ER (Kapvay), which work through different mechanisms (alpha-2 agonists).